JaundiceAHJNCT07575789
Grape Seed Powder and Vitamin C Supplementation for Liver Disease (Acquired Hepatic Jaundice)
A study testing Grape-C supplement in people with Jaundice, run by University of Lahore Hospital (ULH) at 1 site in Pakistan.
Trial summary
Jaundice is a frequent medical problem that affects people of all ages. It is important to note that jaundice is not an actual sickness as such itself but rather a symptom of liver illness brought on by an increase in the quantity of bilirubin circulating in the blood owing to improper metabolism and excretion in the… Read more about this study
- Who is it for?
- Ages 20 to 40 years
- Conditions the study is for
- Jaundice
- What is being tested?
- Grape-C supplement
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 sitePakistan
- Study dates
- 3 Mar 2023to 4 Apr 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Both men and women
- Participants between the ages of 20-40 years will be included
- Patients having signs and symptoms of acquired hepatic jaundice
- Patients having high serum bilirubin, albumin, ALT, AST, ALP levels
- The patient having ALT level more than 10-50 U/L were included
- The participants having AST level above than 0-40 IU/L were included in this study
Show all 10Show fewer
- Patients having ALP level more than 30 - 130 U/L were included in this research study
- Patients having level of bilirubin above than 0 - 21 μmol/L were included in this investigation
- Participants having the range of albumin more than 30-50 g/L were included in this research
- Participants those were underweighted were included
Who cannot join
- Patients who already taking any supplement or medication
- Participants taking any anti-inflammatory medications
- People who were suffering from any other disease
- Patients who have any known allergies
- Non willing patients
- Lactating women
- Pregnant women
- Smokers
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of Grape (VITIS VINIFERA) Seed Powder Along With Vitamin C Supplementation on Serum Bilirubin Levels in Patients With Acquired Hepatic Jaundice
Jaundice is a frequent medical problem that affects people of all ages. It is important to note that jaundice is not an actual sickness as such itself but rather a symptom of liver illness brought on by an increase in the quantity of bilirubin circulating in the blood owing to improper metabolism and excretion in the urine. The aim of this investigation is to investigate the impact of grape (Vitis Vinifera) seed powder along with vitamin C supplementation on serum bilirubin levels in patients with acquired hepatic jaundice. In addition, it's the first research of its kind to investigate the aforementioned function of grape seed extract with vitamin C in healthy individuals specifically.
Read the detailed description
According to my study, the division of patients was done between two groups: one was named as Conventional group (CG) and other was named as Intervention group (IG). The conventional treatment group received only conventional medication and intervention group was given Grape-C capsule with dose of one tablet per day for 4 weeks after lunch along with conventional medication. Grape-C capsule continued for 4 weeks and the data was obtained at the initiation and at end of intervention (after 4th week).
According to my research study results the intervention group had a significant decrease in bilirubin levels, ALT, AST, ALP and increase the albumin and gamma glutamyl transferase (GGT) compared to the conventional group. The p-values for the comparison between pre and post intervention levels were highly significant rather than the conventional groups indicating a statistically significant difference.
- Conditions
- Jaundice
- Being tested
- Grape-C supplement
- Keywords
- Grape (VITIS VINIFERA) Seed Powder and Vitamin C
- Medical subject headings
- Jaundice
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Grape-C supplementDietary supplement
Grape-C supplement purchased from Nutrifactor brand.
| Study group | Role | What they receive |
|---|---|---|
| Conventional group | No intervention | Control group |
| Intervention group | Experimental | Targeted group with intervention Receives: Dietary Supplement: Grape-C supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bilirubin levels
In this study results showed the significant decrease in bilirubin levels in interventional group as compared to the conventional group
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2026
- Study start3 Mar 2023
- Primary completion17 Mar 2023
- Study completion4 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for JaundiceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Lahore Hospital (ULH)
- Sponsor type
- Research network
- Responsible party
- Principal investigator, Aleena Zahid, University of Lahore Hospital (ULH)
- Investigators
- Dr Habib-ur-Rehman Rehman, PhD Food and Nutrition, Study chair, University of Lahore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07575789
- Sponsor's protocol ID
- AZ786
- Other IDs
- University of Lahore
- Acronym
- AHJ
- Status last verified
- May 2026
- First submitted
- 4 May 2026
- Last updated
- 12 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
DOI: 10.4103/1319-3767.65197
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Grape (VITIS VINIFERA) Seed Powder Along With Vitamin C Supplementation on Serum Bilirubin Levels in Patients With Acquired Hepatic Jaundice
- ClinicalTrials.gov ID
- NCT07575789
- Acronym / sponsor ID
- AHJ / AZ786
- Conditions
- Jaundice
- Keywords
- Grape (VITIS VINIFERA) Seed Powder and Vitamin C
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- University of Lahore Hospital (ULH)Research network
- Study start
- 3 Mar 2023 (actual)
- Primary completion
- 17 Mar 2023 (actual)
- Study completion
- 4 Apr 2023 (actual)
- First posted
- 8 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Jaundice is a frequent medical problem that affects people of all ages. It is important to note that jaundice is not an actual sickness as such itself but rather a symptom of liver illness brought on by an increase in the quantity of bilirubin circulating in the blood owing to improper metabolism and excretion in the urine. The aim of this investigation is to investigate the impact of grape (Vitis Vinifera) seed powder along with vitamin C supplementation on serum bilirubin levels in patients with acquired hepatic jaundice. In addition, it's the first research of its kind to investigate the aforementioned function of grape seed extract with vitamin C in healthy individuals specifically.
Detailed description
According to my study, the division of patients was done between two groups: one was named as Conventional group (CG) and other was named as Intervention group (IG). The conventional treatment group received only conventional medication and intervention group was given Grape-C capsule with dose of one tablet per day for 4 weeks after lunch along with conventional medication. Grape-C capsule continued for 4 weeks and the data was obtained at the initiation and at end of intervention (after 4th week).
According to my research study results the intervention group had a significant decrease in bilirubin levels, ALT, AST, ALP and increase the albumin and gamma glutamyl transferase (GGT) compared to the conventional group. The p-values for the comparison between pre and post intervention levels were highly significant rather than the conventional groups indicating a statistically significant difference.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Conventional group | No intervention | –Control group |
| Intervention group | Experimental | Dietary Supplement: Grape-C supplementTargeted group with intervention |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Both men and women
- Participants between the ages of 20-40 years will be included
- Patients having signs and symptoms of acquired hepatic jaundice
- Patients having high serum bilirubin, albumin, ALT, AST, ALP levels
- The patient having ALT level more than 10-50 U/L were included
Key exclusion criteria (8 listed)
- Patients who already taking any supplement or medication
- Participants taking any anti-inflammatory medications
- People who were suffering from any other disease
- Patients who have any known allergies
- Non willing patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Grape-C supplementGrape-C supplement purchased from Nutrifactor brand. | Dietary supplement | Intervention group |
Primary outcome
Bilirubin levels
Time frame: 4 weeks
In this study results showed the significant decrease in bilirubin levels in interventional group as compared to the conventional group
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2026.
- BackgroundDOI: 10.4103/1319-3767.65197
- Ghaffar, S., Naqvi, M. A., Fayyaz, A., Abid, M. K., Khayitov, K. N., Jalil, A. T., Alsaikhan, F., Hammid, A. T., Al-Gazally, M. E., \& Mohammadparast, V. (2022). What is the influence of grape products on liver enzymes? A systematic review and meta-anaLink provided by the sponsor.
- Adikwu, E., \& Deo, O. (2013). Hepatoprotective effect of vitamin C (ascorbic acid)Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Jaundice
Active, not recruitingPhase 1/2
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
End-stage Liver Disease (ESLD), Cirrhosis, Liver
Recruiting
Abdominal Massage for Newborn Jaundice
Neonatal Jaundice
Not yet recruiting
Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation
Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice
Active, not recruiting
Newborn Abdominal Massage to Prevent Hyperbilirubinemia
Newborn Jaundice
Not yet recruitingObservational study
Real-world Evaluation of Different Endoscopic Biliary Drainage Techniques in Patients With Jaundice of Biliopancreatic Malignant Origin
Biliary Drainage, Endoscopic Ultrasound-Guided Drainage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr Habib-ur-Rehman Rehman, PhD Food and Nutrition study chair
University of Lahore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Grape-C supplement in people with Jaundice, run by University of Lahore Hospital (ULH) at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bilirubin levels (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07575789, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2026.